Inozyme Pharma
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -195 | -188 | -182 | |
EBITDA | -25,475 | -22,959 | -25,450 | -21,840 |
EBIT | -25,652 | -23,154 | -25,638 | -22,022 |
Net Income | -27,074 | -24,570 | -27,033 | -23,347 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -19,205 | -24,541 | -23,658 | -24,565 |
Cash | 21,081 | 24,575 | 15,233 | 20,618 |
Basic Shares | 62,811 | 63,276 | 61,943 | 61,772 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1,294 | -1,177 | -1,052 | |
EBITDA | -104,030 | -74,812 | -67,931 | -55,972 |
EBIT | -107,582 | -75,645 | -68,675 | -57,024 |
Net Income | -102,024 | -71,169 | -65,447 | -56,413 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 9,624 | -4,724 | ||
Free Cash Flow | -91,969 | -70,973 | -58,171 | -48,550 |
Cash | 21,081 | 34,588 | 32,915 | 23,316 |
Basic Shares | 62,811 | 51,839 | 37,763 | 23,558 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.42 |
2024-09-30 | -$0.39 |
2024-06-30 | -$0.44 |
2024-03-31 | -$0.38 |
